Article

Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII

Harvard University, Cambridge, Massachusetts, United States
The Journal of Infectious Diseases (Impact Factor: 5.78). 10/1999; 180(3):892-5. DOI: 10.1086/314955
Source: PubMed

ABSTRACT Group B Streptococcus (GBS) types VI and VIII are prevalent among serotypes isolated from pregnant women in Japan. Maternal vaccination with a safe and effective GBS vaccine has been proposed as a rational approach to prevent neonatal GBS disease. Because antibody specific for the capsular polysaccharide (CPS) antigens of GBS is protective, vaccines were developed with purified type VI and VIII CPS coupled to tetanus toxoid. In rabbits the newly synthesized conjugate vaccines elicited high-titered, type-specific antibody that was opsonically active in vitro. Moreover, litters born to mice actively vaccinated with the conjugate vaccines, in contrast to uncoupled CPS or saline, were protected against an ordinarily lethal challenge of GBS of homologous serotype. GBS types VI and VIII conjugate vaccines of the design presented may be important components of a multivalent GBS vaccine for use in regions where these serotypes predominate.

0 Bookmarks
 · 
56 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gram-positive streptococci are non-motile, chain-forming bacteria commonly found in the normal oral and bowel flora of warm-blooded animals. Over the past decade, a proteomic approach combining 2-DE and MS has been used to systematically map the cellular, surface-associated and secreted proteins of human pathogenic streptococcal species. The public availability of complete streptococcal genomic sequences and the amalgamation of proteomic, genomic and bioinformatic technologies have recently facilitated the identification of novel streptococcal vaccine candidate antigens and therapeutic agents. The objective of this review is to examine the constituents of the streptococcal cell wall and secreted proteome, the mechanisms of transport of surface and secreted proteins, and describe the current methodologies employed for the identification of novel surface-displayed proteins and potential vaccine antigens.
    PROTEOMICS - CLINICAL APPLICATIONS 02/2008; 2(3):387 - 410. DOI:10.1002/prca.200780048 · 1.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The immunogenicity identification of epidemic strain is important for the development and application of vaccine. In this study, 85 Streptococcus agalactiae prevalent strains from the tilapia main cultured areas of China were distributed among 10 distinct PFGE genotypes (A-J). For each genotype, one representative strain (S.a(A)-S.a(J)) was selected to develop an inactivated whole-cell bacterial vaccine (V(A)-V(J)), which then underwent a protective immunity test. V(A)-V(J) showed similar relative percent survival (RPS) to the homologous or heterologous strains with the identical genotype, while the average RPS among V(A)-V(J) protecting against itself genotype strains showed large differences (44.71-98.81%). The RPS of V(A)-V(J) vaccinated fish against infections by the mixture of S.a(A)-S.a(J) at 15 days post vaccination (dpv) was ranged from 13.33% to 60.00%, and V(B), V(D), V(F), and V(G) showed the highest RPS of 60.00%, 46.67%, 53.33% and 60.00% respectively. V(B), V(D) and V(G) have their own specific protection scope, V(B) showed strong protective immunity to infections caused by A-D, F, G and J (53.57-100%), and V(G) showed strong protective immunity to C-H and J (50.00-100%), whereas V(D) showed weak protective immunity to all non-self genotype strains (14.81-36.67%). The results of the combined vaccination showed that V(G)+V(B) group had wider protection scope and higher RPS value than V(G)+V(D) group. Our results demonstrated that the protective immunity of S. agalactiae from tilapia was not only associated with their serotypes, but also related to their PFGE genotypes. It is difficult to acquire a single vaccine candidate strain that can protect against all genotype strains from the same serotype.
    Vaccine 08/2012; 30(42):6088-92. DOI:10.1016/j.vaccine.2012.07.044 · 3.49 Impact Factor
  • Source